RPRX

Royalty Pharma is the largest buyer of biopharmaceutical royalties, owning royalty interests in dozens of commercial and development-stage products. The company acquires royalty streams from pharmaceutical companies and academic institutions, providing upfront capital in exchange for future revenue shares. Royalty Pharma's portfolio includes treatments across therapeutic areas including immunology, infectious disease, oncology, and rare diseases. The firm operates a diversified revenue model based on the commercial success of approved therapies.